Symlux Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -78.76%
- Profit Growth 93.63%
- Ebitda 95.34%
- Net Worth -6.80%
- Total Assets -34.45%
About Symlux Pharmaceuticals
Symlux Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 September 2015 (Nine years and five months 1 days old ). Its registered office is in Thane, Maharashtra.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Santosh Joshi and Amol Nilakh serve as directors at the Company.
Company Details
-
LocationThane, Maharashtra
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74999MH2015PTC268271
-
Company No.
268271
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
09 Sep 2015
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Symlux Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amol Nilakh
|
Director | 19-Oct-2015 | Current |
|
Santosh Joshi
|
Director | 23-Mar-2016 | Current |
Financial Performance of Symlux Pharmaceuticals.
Symlux Pharmaceuticals Private Limited, for the financial year ended 2018, experienced significant reduction in revenue, with a 78.76% decrease. The company also saw a substantial improvement in profitability, with a 93.63% increase in profit. The company's net worth dipped by a decrease of 6.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Symlux Pharmaceuticals?
In 2018, Symlux Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Prowill Pharmaceuticals Private LimitedSantosh Joshi is a mutual person
-
Allcure Health Care Private LimitedSantosh Joshi is a mutual person
-
Accon Lifesciences Private Limited
Santosh Joshi is a mutual person
-
Ascons Nilakh Plus Llp
Amol Nilakh is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Symlux Pharmaceuticals?
Unlock and access historical data on people associated with Symlux Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Symlux Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Symlux Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
